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INTRODUCTION
The Asian Society of Gynecologic Oncology International 
Workshop 2014 on gynecologic oncology was held in Asan 
Medical Center, Seoul, Korea on the 23rd to 24th August 
2014. The workshop was aimed at enhancing the knowledge 
of Asian young doctors on gynecologic oncology, sharing 
up-to-date knowledge about the management and care of 
gynecologic cancer patients in Asian countries, and renewing 
old acquaintances and making new ones. A total of 179 par-
ticipants from 17 countries (Korea, Japan, China, Indonesia, 
Nepal, India, Malaysia, Myanmar, Thailand, Zimbabwe, Philip-
pines, Mongolia, Hong Kong, Singapore, Sri Lanka, Taiwan, 
and USA) participated in the workshop, which comprised 
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Abstract
The Asian Society of Gynecologic Oncology International Workshop 2014 on gynecologic oncology was held in Asan Medical 
Center, Seoul, Korea on the 23rd to 24th August 2014. A total of 179 participants from 17 countries participated in the workshop, 
and the up-to-date findings on the management of gynecologic cancers were presented and discussed. This meeting focused 
on the new trends in the management of cervical cancer, fertility-sparing management of gynecologic cancers, surgical 
management of gynecologic cancers, and recent advances in translational research on gynecologic cancers.
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27 lectures divided into seven sessions and two seminars 
(Supplementary 1–3).
SESSION 1. NEW TRENDS IN THE MANAGEMENT OF CERVICAL 
CANCER
1. Updates on cervical cancer prevention and control 
Cervical cancer is still the most common gynecologic 
cancer in the world despite the adoption of vaccination 
against human papilloma virus (HPV) (primary prevention) 
and a nationwide screening program (secondary prevention) 
for cervical cancer in many countries. Cervical cancer can 
be prevented effectively by HPV vaccines, but the global 
implementation of HPV vaccines is still ongoing. Hextan YS 
Ngan suggested several reasons for this, including the cost of 
HPV vaccines, doubts about the efficacy of HPV vaccines, and 
the length of protection. Although population vaccination 
in several countries has lowered the incidence of abnormal 
cervical cytology, the need for colposcopy, and the treatment 
for high-grade cervical intraepithelial neoplasia [1], screening 
is still recommended after vaccination and this adds to the 
cost. Recent clinical trials have suggested that two doses 
instead of three doses of the vaccine would reduce cost [2,3]. 
Newly developed nanovalent vaccines may prevent up to 
90% of high-grade cervical intraepithelial neoplasia and thus it 
is probably acceptable not to continue screening. For cervical 
cancer screening, the high-risk HPV test is more sensitive than 
conventional cytology screening and was recently approved 
as a primary screening tool [4]. The high negative predictive 
value of the high-risk HPV test can lengthen the intervals 
between screenings; however, because the management 
of cases with a positive HPV test result has not been imple-
mented, a second triage to reduce unnecessary colposcopy 
and treatment is required.
2. Tailored radiation therapy: intensity-modulated  
radiotherapy/proton therapy
Radiotherapy has been an important part of the manage-
ment of gynecologic cancers for a long time and reduces 
the loco-regional failure rate and improves survival outcome. 
New techniques for delivering radiation to targets, including 
intensity-modulated radiotherapy (IMRT) and proton therapy, 
for the management of gynecologic cancers were reviewed 
and discussed in the session. IMRT is better at reducing the 
delivery of radiation to adjacent normal tissue, such as rectum, 
bladder, and small bowel, and results in the delivery of a high-
er tumor dose compared with conventional or 3-dimensional 
conformal radiotherapy. It also can probably provide benefits 
in terms of increased tumor control and decreased toxicity to 
normal tissues; however, the study of the clinical significance 
of IMRT in the management of gynecologic cancers has been 
limited in several reports [5-9]. A randomized phase 3 clinical 
trial is ongoing to compare standard radiotherapy to IMRT 
for the postoperative treatment of endometrial and cervical 
cancer (RTOG protocol 1203). Proton therapy completes 
energy delivery at a defined depth and has no exit energy 
after the Bragg peak. It can decrease the irradiated volume 
and reduce the dose to adjacent normal tissues beyond 
that achievable by IMRT; however, there is no clinical data to 
confirm that proton therapy reduces normal tissue toxicity. 
Photon therapy still remains mostly an investigational tool for 
the management of gynecologic cancers. Prospective clinical 
trials are required to evaluate the efficacy of IMRT and proton 
therapy in the management of gynecologic cancers.
3. The evolution of treatment methods for cervical cancer 
in China
The recent evolution in methods for the treatment of cervical 
cancer was presented by Zeyi Cao. In the past, radiotherapy 
was the mainstay of cervical cancer treatment, but the use 
of surgery, IMRT, concurrent chemoradiation therapy, and 
neoadjuvant chemotherapy has increased. During the last 
three decades, the proportion of young patients with cervical 
cancer has increased from 10% to 40%. From the perspective 
of quality of life, surgery has now become the primary treat-
ment modality in approximately 90% of patients with cervical 
cancer. Dr. Cao reported that new techniques to treat cervical 
cancer would probably be introduced in the near future, in-
cluding personalized function-sparing surgery and minimally 
invasive surgery (laparoscopic and robotic surgery).
SESSION 2. SPECIAL ISSUES 1: PRESERVING FERTILITY IN 
GYNECOLOGIC CANCER PATIENTS
Young women with early gynecologic cancers have excellent 
survival outcomes when treated with current treatment mo-
dalities; however, quality of life is as important as survival out-
come for these patients. Recently, increasing interest has been 
given to improving the quality of life of gynecologic cancer 
patients. Fertility preservation is one of the most important 
quality-of-life issues in young women with early gynecologic 
cancers. In this session, up-to-date findings regarding fertility-
preserving management for early cervical, endometrial, and 
ovarian cancer were thoroughly reviewed and discussed.
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1. Fertility preservation in cervical cancer
Fertility-preserving radical trachelectomy has been accepted 
as a reasonable alternative treatment for young women 
with early cervical cancer who wish to preserve their fertility. 
Currently, several types of surgical approaches for radical 
trachelectomy are used in real practice, including vaginal, ab-
dominal, laparoscopic, and robotic radical trachelectomy. The 
use of vaginal radical trachelectomy is limited to small cervical 
cancers with a tumor size <2 cm because the recurrence rate 
is significantly higher when the tumor size is >2 cm [10,11]; 
however, because wider extirpation of parametrial tissue has 
become possible using other surgical approaches including 
abdominal, laparoscopic, and robotic radial trachelectomy 
[12], recent investigators have suggested that radical trach-
electomy be extended to selected patients with a tumor size 
>2 and <4 cm [13-15].
2. Fertility preservation in endometrial cancer
Fertility-preserving management using oral progestin is 
regarded as a safe alternative treatment for selected young 
women with early endometrial cancer who want to preserve 
their fertility [16,17]. Indication of this treatment is now limited 
to well-differentiated, endometrioid-type, endometrial cancers 
confined to the endometrium [16,17]. Definitive surgical man-
agement should be considered after the completion of family 
planning because of the high rate of recurrence [16,17]. Re-
cent reports have pointed to promising pregnancy outcomes 
[16,18] and the safety of the treatment for more advanced 
and recurrent disease [19,20]; however, further studies will be 
required to define the optimal agents and dosing schedule, 
as well as to determine the safety of this treatment for more 
advanced disease and recurrent disease.
3. Fertility preservation in ovarian cancer
Fertility-preserving surgery is a well-established treatment 
modality in young women with borderline ovarian tumors 
and malignant ovarian germ cell tumors; however, the ac-
ceptance of fertility-preserving surgery for the management 
of invasive epithelial ovarian cancer occurred later than its 
acceptance for the management of borderline ovarian tumors 
and malignant ovarian germ cell tumors. Although there has 
never been a prospective trial to evaluate the role of fertility-
sparing surgery in invasive epithelial ovarian cancer, currently 
available evidence suggests that fertility-sparing surgery is 
safe in selected young women with early epithelial ovarian 
cancer. It can be safely performed on patients with non-clear 
cell histology, stage IA to IC (grade 1 to 2) disease, and clear 
cell histology, stage IA disease [21,22].
SESSION 3. SURGERY FOR GYNECOLOGIC CANCER 1
Recent advances in surgical management of gynecologic 
cancers were reviewed and discussed in Session 3 and 6. This 
session focused on the role of sentinel lymph node mapping 
and cytoreductive surgery for invasive epithelial ovarian can-
cer, and pelvic exenteration and laterally extended endopelvic 
resection (LEER) for recurrent cervical cancer.
1. Sentinel lymph node mapping in endometrial cancer 
The concept of the sentinel lymph node has been devel-
oped for the surgical management of several types of cancers. 
In early endometrial cancer, the role of pelvic lymph node 
dissection is limited to a staging role because two randomized 
clinical trials failed to show the survival benefit of pelvic lymph 
node dissection [23]. Therefore, accurate staging of lymph 
node status while minimizing complications associated with 
pelvic lymph node dissection is important; thus the sentinel 
lymph node concept is being evaluated. Several types of sen-
tinel lymph node mapping techniques were reviewed in this 
lecture. Although there exists insufficient evidence to support 
their large-scale deployment and significant disagreement re-
garding their use, they may be considered in selected patients 
with early endometrial cancer. Increasing surgeon exposure 
to, and experience with, these techniques will be important 
for their future success. Future prospective studies should try 
to confirm the role of sentinel lymph node mapping in early 
endometrial cancer.
2. Cytoreductive surgery in ovarian cancer: pelvis and 
upper abdomen
Surgery has an important role to play in the management of 
all epithelial ovarian cancers. The size of a residual tumor after 
cytoreductive surgery is the single most important prognostic 
factor and the only prognostic factor that the surgeon can 
modify. Surgical techniques for optimal cytoreduction of 
pelvic disease and abdominal disease were reviewed and 
shown in surgical videos in two lectures. Recently, the goal of 
optimal cytoreduction has changed from that of obtaining a 
level of small residual disease <1 cm to that of obtaining no 
grossly visible tumor, because many studies have confirmed 
the further survival benefit of complete cytoduction over that 
of leaving a small residual disease <1 cm [24].
3. Pelvic exenteration and LEER for recurrent cervical cancer
Pelvic exenteration is sometimes the last chance of obtain-
ing a cure for recurrent cervical cancer in the irradiated pelvis. 
If the tumor is located in the lateral side of the pelvis, LEER 
can be used as an alternative surgical approach. The surgical 
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techniques and outcomes of pelvic exenteration and LEER 
in recurrent cervical cancer were reviewed in this lecture. 
The mortality rate has decreased continuously from 25% to 
less than 5%, and the 5-year survival rate has continuously 
improved from 22% to more than 50% [25]. Considering the 
absence of other curable treatment modalities for recurrent 
cervical cancer, these outcomes are very promising.
SESSION 4. RECENT ADVANCES IN TRANSLATIONAL RESEARCH
This session focused on the recent advances in translational 
research for gynecologic cancers, including advances in the 
use of biomarkers, The Cancer Genome Atlas (TCGA), microR-
NAs, and patient-derived tumor xenograft (AVATAR) models.
1. Biomarkers for epithelial ovarian cancer
Research into new biomarkers for the screening, diagnosis, 
disease monitoring, and surveillance of ovarian cancer has 
drawn increasing interest from doctors and surgeons who 
treat this disease. Although numerous studies have been 
performed in this direction, obtaining an early diagnosis of 
ovarian cancer is still challenging. The use of multiple serum 
markers for early diagnosis has not yet been established. 
Recently, two algorithms to estimate the risk of ovarian cancer 
in women with a pelvic mass have been approved (ROMA and 
OVA1). CA-125 is still a useful marker for prognosis and disease 
monitoring.
2. The cancer genome atlas: TCGA data mining
TCGA is a large-scale collaborative effort to understand the 
molecular basis of cancer through the application of genome 
analysis technologies, including, but not limited to, identifying 
mutations in DNA sequences, copy number variation, and 
alterations in methylation status. Considerable research has 
been expended in identifying the genomic changes in more 
than 20 different types of human cancer, including gyneco-
logic cancers, and analyzing hundreds of samples for each 
type of cancer. By comparing the DNA in samples of normal 
tissue with those in cancer tissues taken from the same patient, 
researchers have identified changes specific to particular 
cancers. By connecting specific genomic changes with specific 
outcomes, researchers will be able to develop more effective, 
individualized ways of helping each cancer patient.
3. MicroRNA strategy in ovarian cancer
MicroRNAs are a class of small non-coding RNAs that regulate 
the translation of mRNAs by inhibiting translation. Abnormal 
expression of microRNA has been observed in gynecologic 
malignancies including ovarian cancer. Several microRNA pro-
filing studies have identified the changes in miRNA patterns 
that take place during ovarian cancer development and some 
of them may represent targets for therapy. In addition, some 
of the microRNA patterns may have prognostic significance. A 
better understanding of microRNA expression may provide a 
new way for the detection, diagnosis, and treatment of ovarian 
cancer.
4. Patient-derived tumor xenograft model (AVATAR) model 
for gynecologic cancer
A patient-derived tumor xenograft model is built by trans-
planting the patient’s tumor tissue into an immunodeficient 
mouse. In this lecture, the applications of patient-derived 
tumor xenografts in gynecologic cancer research were pre-
sented. This model better preserves the morphology and gene 
expression of the patient’s tumor than conventional xenografts 
established using cancer cell lines. The patient-derived tumor 
xenograft model offers a powerful tool for studying tumor biol-
ogy and a good platform for the establishment of personalized 
medicine for patients with gynecologic cancers.
SESSION 5. SPECIAL ISSUES 2: UPDATES ON THE MANAGEMENT 
OF GYNECOLOGIC CANCERS
1. Current practice for selecting and testing ovarian cancer 
patients for BRCA mutations
Hereditary ovarian cancer accounts for 5% to 10% of all 
ovarian cancers, and germline mutations in BRCA1 and BRCA2 
are fundamental defects underlying hereditary ovarian cancer, 
where they account for approximately 10% of all cases. A 
PARP inhibitor has been reported to be effective in patients 
with recurrent epithelial ovarian cancer and germline BRCA 
mutations. According to TCGA data, 14% of serous ovarian 
cancer had germline mutations and 6% had somatic mutation 
in BRCA. In Korea, the prevalence of germline mutations in 
BRCA1 and BRCA2 is approximately 25% to 33% in those with 
a family history and approximately 10% in those without a 
family history. Therefore, personalized medicine based on 
genetic information including BRCA status is an important 
part of ovarian cancer treatment.
2. Implementation of HPV vaccination: the Malaysian 
experience
The implementation of HPV vaccination in low- or middle-
income countries has encountered many hurdles, including 
that of cost. Malaysia was the first middle-income country in 
the world to implement a national HPV vaccination program 
Jeong-Yeol Park, et al.
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in 2010. It is a school-based vaccination program targeting 
girls attending year seven in schools (13-year-old girls). Immu-
nization in the clinic is proposed to 13-year-old out-of-school 
girls. This program was very successful as 95.9% and 97.9% of 
parents gave consent to their daughters to be vaccinated and 
97.9% and 95.9% of girls who obtained parental consent com-
pleted all three courses of the vaccination in 2010 and 2011, 
respectively. In 2012, a catch-up vaccination program was 
introduced targeting girls aged 18 years. Suresh Kumarasamy 
suggested that the reasons for the success of this program 
included endorsement and recommendation by the medical 
profession, political will and leadership, the involvement of 
stakeholders early on in the program, predicting and manag-
ing potential risks, monitoring implementation closely, a 
good existing school health program, the involvement of the 
Ministry of Education, and giving sufficient information about 
the vaccine and its safety to parents.
3. Surgery for early-stage cervical cancer: toward a  
less-radical strategy
Radical hysterectomy has been used for the standard surgi-
cal management of early cervical cancer. All patients with 
early cervical cancer undergo radical surgery, which causes 
significant urinary and interstitial morbidity regardless of the 
extent of the disease. There is no high level of evidence re-
garding current surgical management of early cervical cancer. 
An effort to tailor the extent of surgery to the extent of early 
cervical cancer has been attempted recently. The guidelines 
for the surgical management of breast cancer are a good 
example. These guidelines were established based on results 
of clinical trials. In this lecture, clinical trials aiming at tailoring 
the extent of surgery to the extent of early cervical cancer 
were presented, along with a review of literature.
4. Ovarian cancer screening
In this lecture, the current status of ovarian cancer screening 
was presented and the future directions of ovarian cancer 
screening were reviewed and discussed. Ovarian cancer 
screening has two aims: the detection of early-stage disease 
and the differentiation of benign tumors from malignant ovar-
ian tumors. Practical tools for ovarian cancer screening include 
screening for serum tumor markers and ultrasound imaging; 
however, data from recent, large-scale clinical trials do not 
support the use of these tools for the cost-effective screening 
of ovarian cancer. Multimodal screening may be beneficial 
in high-risk women and is recommended by professional 
groups. Algorithms using HE4 were found to be beneficial for 
discriminating benign from malignant ovarian tumors.
SESSION 6. SURGERY FOR GYNECOLOGIC CANCER 2
This session focused on minimally invasive surgery and 
fertility-preserving abdominal radical trachelectomy. These 
two approaches now dominate the surgical management of 
gynecologic cancers.
1. Laparoscopic radical hysterectomy
The adoption of laparoscopic surgery for the surgical manage-
ment of cervical cancer has been slower than that of endo-
metrial cancer because of the technical difficulties associated 
with laparoscopic surgery and the diversity of the approaches 
employed; however, recent improvements in laparoscopic 
instruments and surgical techniques have made laparoscopic 
radical hysterectomy the preferred surgical approach for the 
surgical management of early cervical cancer. Laparoscopic 
radical hysterectomy has better surgical outcomes than other 
methods without affecting survival outcomes or increasing 
the number of complications. In this lecture, the outcomes 
of laparoscopic radical hysterectomy were reviewed and the 
surgical technique of laparoscopic radical hysterectomy was 
shown in a surgical video. At earlier periods, the use of lapa-
roscopic radical hysterectomy was limited to small cervical 
tumors <2 cm [26,27]; however, with the increase in surgical 
experience, the radicality of laparoscopic radical hysterectomy 
has become comparable to that of open radical hysterectomy 
[28]. Currently, the indication for radical hysterectomy has 
been extended to cervical tumors >4 cm [29]. Recent studies 
suggest that the benefit of laparoscopic surgery extends to 
elderly and obese patients [30,31].
2. Abdominal radical trachelectomy: where are we now?
Vaginal radical trachelectomy is now an accepted treatment 
modality for the management of young women with early 
cervical cancer who wish to preserve their fertility; however, 
because of the limited surgical radicality and the long learning 
curve for vaginal radical trachelectomy, abdominal radical 
trachelectomy has been introduced to overcome these limita-
tions. In this lecture, the experiences of Japanese doctors with 
abdominal radical trachelectomy were presented, together 
with a review of the literature.
3. Laparoscopic surgery in early-stage ovarian cancer
Laparotomy with a vertical midline abdominal incision has 
been the standard surgical procedure for the surgical staging 
of ovarian cancer. Over the last two decades, however, mini-
mally invasive surgical techniques have dramatically improved 
the surgical management of ovarian cancer and have been 
frequently applied in this context, although many physicians 
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continue to debate the use of laparoscopic surgery for ovarian 
cancer. Since Querleu and Leblanc [32,33] first described 
laparoscopic surgical staging for ovarian cancer in 1994, many 
studies have reported the feasibility and safety of laparoscopic 
surgical staging [34-37]; however, there has never been a 
prospective randomized trial until now and the evidence for 
a role for laparoscopic surgery in the management of ovarian 
cancer is still insufficient [38]. Future prospective trials should 
help confirm the feasibility and safety of laparoscopic surgical 
staging in ovarian cancer.
4. Robotic surgery in cervical cancer
Robotic surgery is gaining popularity in the surgical manage-
ment of gynecologic cancers. Although the cost of this type 
of surgery is the biggest hurdle preventing its popularity in 
Asian countries, it could become the dominant paradigm in 
the near future for the surgical management of gynecologic 
cancers. In this lecture, the status of robotic surgery for 
the management of gynecologic cancers and the surgical 
outcomes associated with this treatment modality were 
reviewed, and surgical techniques were presented in a video. 
Because robotic surgery has similar outcomes to laparoscopic 
surgery, but has several advantages over laparoscopic surgery, 
including a short learning curve, the use of robotic surgery is 
expected to continue to increase in the future.
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Day 1    23 August, 2014 (Saturday)
Time Titles Chair/Speaker
08:00-08:45 Registration
08:45-09:00 Opening remark Joo-Hyun Nam, President of ASGO
Congratulatory remark Toshiharu Kamura,  Immediate past president of ASGO
 Session I New trends in the management of cervical cancer Chair: Toshiharu Kamura (Japan),  
             Soon-Beom Kang (Korea)
09:00-09:25 Updates in cervical cancer prevention and control Hextan YS Ngan (Hong Kong)
09:25-09:50 Tailored radiation therapy: IMRT / Proton therapy Won Park (Korea)
09:50-10:15 The evolution of treatment methods for cervical cancer in China Zeyi Cao (China) 
10:15-10:45 Break
 Session II Special issues I: Fertility preservation in gynecologic cancers Chair: Yasuhiro Udagawa (Japan), Hee-Sug Ryu (Korea)
10:45-11:10 Fertility preservation in cervical cancer Xiaohua Wu (China)
11:10-11:35 Fertility preservation in endometrial cancer Jeong-Yeol Park (Korea)
11:35-12:00 Fertility preservation in ovarian cancer Woong Ju (Korea)
Luncheon seminar (Supported by Janssen Korea) Chair: Se-Jun Han (Korea)
12:00-12:20 Role of pegylated liposomal doxorubicin  in recurrent  
  ovarian cancer
Soo-Young Hur (Korea)
12:20-13:30 Lunch
 Session III Surgery for gynecologic cancer (I) Chair: Kazunori Ochiai (Japan), Duk-Soo Bae (Korea)
13:30-13:55 Sentinel lymph node mapping in endometrial cancer Hyun Hoon Chung (Korea)
13:55-14:20 Cytoreductive surgery in ovarian cancer: pelvis Suk-Joon Chang (Korea)
14:20-14:45 Cytoreductive surgery in ovarian cancer: upper abdomen Sang Yoon Park (Korea)
14:45-15:10 Pelvic exenteration and LEER for recurrent cervical cancer Sang-Young Ryu (Korea)
15:10-15:40 Break
 Session IV Recent advances in translational research Chair: Efrén Domingo (Philippines),  
Seung Cheol Kim (Korea)
15:40-16:05 An addition to biomarkers for epithelial ovarian cancer Jae-Hoon Kim (Korea)
16:05-16:30 The cancer genome atlas: TCGA data mining Chi-Heum Cho (Korea)
16:30-16:55 MicroRNA strategy in ovarian cancer Keun Ho Lee (Korea)
16:55-17:20 Patient-derived tumor xenograft (AVATAR) model for  
  gynecologic cancer
Jeong-Won Lee (Korea)
18:00 Welcome Dinner
Jeong-Yeol Park, et al.
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Day 2    24 August, 2014 (Sunday)
Time Titles Chair/Speaker
 Session V Special issues II: Updates in the management of gynecologic 
cancers
Chair: Ikuo Konishi (Japan), Soon-Do Cha (Korea)
09:00-09:25 HPV vaccination: the Malaysian experience Suresh Kumarasamy (Malaysia)
09:25-09:50 Surgery for early stage cervical cancer: 
  toward less-aggressive way
Jae-Weon Kim (Korea)
09:50-10:15 Ovarian cancer screening Sarikapan Wilailak (Thailand)
10:15-10:40 Current practice for selecting and testing ovarian cancer 
  patients for BRCA mutation
Byeong-Gie Kim (Korea)
10:40-11:00 Break
 Session VI Surgery for gynecologic cancer (II) Chair: Mohamad Farid Aziz (Indonesia), 
Kimio Ushijima (Japan) 
11:00-11:25 Laparoscopic radical hysterectomy Joo-Hyun Nam (Korea)/Dae-Yeon Kim (Korea)
11:25-11:50 Abdominal radical trachelectomy: where are we now? Ikuo Konishi (Japan)
11:50-12:15 Laparoscopic surgery in early stage ovarian cancer Jae-Kwan Lee (Korea)
12:15-12:40 Robotic surgery in cervical cancer Kung-Liahng Wang (Taiwan) 
12:40-14:00 Lunch
 Session VII Medical writing & reviewing Chair: Yin Nin Chia (Singapore), Young Tae Kim (Korea)
14:00-14:20 Common mistakes by Asian medical writers Masao Okazaki (USA)
14:20-14:40 Manuscript preparation before submitting to the JGO Sokbom Kang (Korea)
14:40-15:00 What do the editors expect of the reviewers? Chul-Min Lee (Korea)
15:00-15:20 Closing remark Hee-Sug Ryu,
Congress President of the 4th Biennial Meeting of ASGO
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